Is Oxyntomodulin legal in Australia?

Glucagon with eight extra amino acids on the end, which turns it into a weak dual agonist at both glucagon and GLP-1 receptors. The natural template for every GLP-1 and glucagon dual agonist.

Oxyntomodulin is the glucagon sequence plus an eight-residue tail, KRNRNNIA. That single structural fact explains its entire pharmacology and is why it belongs on this site.

Mechanism: A weak dual agonist at the glucagon receptor and the GLP-1 receptor, with no dedicated receptor. The proposed appeal of that combination is that GLP-1 receptor agonism suppresses appetite while glucagon receptor agonism raises energy expenditure, so the pair might reduce intake and increase output at once.

Regulatory history: Not approved and not marketed anywhere. Its therapeutic relevance is as a design template.

Registers or lists therapeutic goods on the ARTG and schedules substances in the Poisons Standard. Many peptides are Schedule 4 (prescription only), so possession without a prescription and personal importation are restricted even when no product is registered.

The classification above is the The Longevity Archive reading of Therapeutic Goods Administration listings for Oxyntomodulin at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.